A Small-Molecule Mitochondrial Complex I Modulator Improves Behavioral and Mitochondrial Dysfunction in Schizophrenia

Area of Science:

• Neuroscience
• Mitochondrial Biology
• Pharmacology

Background:

• Mitochondrial dysfunction is implicated in schizophrenia pathophysiology.
• Weak inhibition of mitochondrial complex I (mtCI) shows neuroprotective effects in other neurodegenerative models.
• The therapeutic potential of mtCI inhibition in schizophrenia remains unexplored.

Purpose of the Study:

• To investigate if weak mtCI inhibition can ameliorate mitochondrial and behavioral deficits in a mouse model of schizophrenia.
• To explore the underlying molecular mechanisms, focusing on mitochondrial biogenesis regulators.

Main Methods:

• Utilized a mouse model with four copies of the Gldc gene, a model for schizophrenia.
• Administered CP2, a weak mtCI inhibitor, for 8 weeks.
• Assessed behavioral phenotypes using Y-maze, startle habituation, and social interaction tests.
• Analyzed protein expression of PGC-1α and VDAC1 via Western blotting.

Main Results:

• CP2 treatment reversed deficits in spontaneous alternation, startle habituation, and social novelty.
• CP2 administration normalized reduced expression of PGC-1α, a key regulator of mitochondrial biogenesis.
• CP2 treatment also reversed reduced VDAC1 expression, crucial for mitochondrial-cytosolic metabolite exchange.

Conclusions:

• Weak inhibition of mtCI with CP2 effectively reverses behavioral and molecular deficits in a mouse model of schizophrenia.
• Targeting mitochondrial dysfunction by enhancing mitochondrial biogenesis and function presents a promising therapeutic avenue for schizophrenia.